Article Text

Download PDFPDF
Cohort study
Perioperative selective serotonin reuptake inhibitor administration is a marker of poor outcomes after surgery
  1. Natalie F Holt
  1. Department of Anesthesiology, Yale School of Medicine, New Haven, Connecticut, USA
  1. Correspondence to: Dr Natalie F Holt, Department of Anesthesiology, Yale School of Medicine, 333 Cedar Street, TMP 3, New Haven, CT 06520, USA; natalie.holt{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrlCrossRef


With a lifetime prevalence of 6–11%, depression is a common comorbidity in surgical patients. Owing to their high efficacy and safety, selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed antidepressants.1 Some studies suggest that SSRIs may increase surgical bleeding. However, SSRI discontinuation may exacerbate psychiatric illness or precipitate withdrawal symptoms. Therefore, controversy exists over their perioperative management.


Auerbach and colleagues used administrative data from 530 416 patients in 375 US hospitals to determine the association between SSRI use and adverse surgical outcomes. They applied sensitivity analyses and propensity matching to control for the presence of …

View Full Text


  • Competing interests None.